Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904397 · ClinicalTrials.gov registry record · Phase 4
Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
NCT00904397: Clinical Trial Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00904397 is a Phase 4 study that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904397, a Phase 4 study, was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
Study Summary
Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chronic axial LBP with and without radiation.
Interventions
- DRUG Celecoxib
- DRUG Lidoderm®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2004-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904397
The ClinicalTrials.gov registry entry for NCT00904397 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00904397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904397 about?
NCT00904397 is a clinical study titled "Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain". Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chro...
What is the current status of trial NCT00904397?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2004-07.
What interventions are being tested in trial NCT00904397?
The interventions under investigation include: Celecoxib (DRUG), Lidoderm® (DRUG).
Who is sponsoring clinical trial NCT00904397?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.